ImmunoPrecise Antibodies Ltd (IPA)
0.4599
-0.02
(-4.19%)
USD |
NASDAQ |
Nov 14, 16:00
0.50
+0.04
(+8.72%)
After-Hours: 20:00
ImmunoPrecise Antibodies Revenue (Quarterly): 3.842M for July 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
July 31, 2024 | 3.842M |
April 30, 2024 | 4.758M |
January 31, 2024 | 4.606M |
October 31, 2023 | 4.527M |
July 31, 2023 | 4.259M |
April 30, 2023 | 4.145M |
January 31, 2023 | 3.834M |
October 31, 2022 | 3.895M |
July 31, 2022 | 3.640M |
April 30, 2022 | 4.133M |
January 31, 2022 | 3.800M |
October 31, 2021 | 3.754M |
July 31, 2021 | 3.734M |
April 30, 2021 | 3.871M |
January 31, 2021 | 3.508M |
October 31, 2020 | 3.596M |
July 31, 2020 | 2.752M |
April 30, 2020 | 3.016M |
January 31, 2020 | 3.065M |
October 31, 2019 | 2.388M |
July 31, 2019 | 2.045M |
April 30, 2019 | 1.983M |
January 31, 2019 | 2.023M |
October 31, 2018 | 2.084M |
July 31, 2018 | 2.202M |
Date | Value |
---|---|
April 30, 2018 | 1.422M |
January 31, 2018 | 1.362M |
October 31, 2017 | 1.052M |
July 31, 2017 | 0.4471M |
April 30, 2017 | 0.4469M |
January 31, 2017 | 0.383M |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.752M
Minimum
Jul 2020
4.758M
Maximum
Apr 2024
3.828M
Average
3.834M
Median
Jan 2023
Revenue (Quarterly) Benchmarks
Aurinia Pharmaceuticals Inc | 67.77M |
Edesa Biotech Inc | -- |
Lexaria Bioscience Corp | 0.084M |
Xenon Pharmaceuticals Inc | -- |
ESSA Pharma Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -2.920M |
Total Expenses (Quarterly) | 7.220M |
EPS Diluted (Quarterly) | -0.1095 |
Enterprise Value | 11.89M |
Gross Profit Margin (Quarterly) | 44.77% |
Profit Margin (Quarterly) | -75.98% |
Earnings Yield | -169.7% |
Normalized Earnings Yield | -82.88 |